跳至主要内容
临床试验/NCT00908778
NCT00908778Unknown3 期

A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.

Vitreoretinal Technologies, Inc.5 个研究点 分布在 2 个国家目标入组 160 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
160
试验地点
5
主要终点
Ultrasound, OCT, and clinical exam

研究概览

简要总结

The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects with a history of systemic diabetes(type I,or II)
  • Subject with a documented history of Non- proliferative Diabetic Retinopathy(NPDR)
  • Subjects with no or partial PVD at baseline exam in study eye.

排除标准

  • Subjects with retinal pathology in the study eye other then (NPDR)
  • Subjects with high myopia in the study eye
  • Subjects who have monocular vision or central lateral vision of 20/200 or worse BCVA in the non-study eye.
  • Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less then 6 months prior to study enrollment.
  • Subjects that have either vitrectomy surgery, intavitreal injections, or laser treatments in the study eye.

研究组 & 干预措施

Vitreosolve I

Experimental

Intravitreal injection

干预措施: Vitreosolve (Drug)

Vitreosolve

Experimental

Intravitreal injection

干预措施: Vitreosolve (Drug)

结局指标

主要结局

Ultrasound, OCT, and clinical exam

时间窗: 6 months

次要结局

  • Ultrasound ,OCT ,Safety, and Clinical Exam(6 months)

研究者

申办方类型
Industry

研究点 (5)

Loading locations...

相似试验